stockrow
Sunday 8 November 2026
Export AMRN’s income statement to Excel — free account
Amarin Corporation PLC
AMRNHealthcare Drug Manufacturers General
Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024.
- Revenue
- −20.4%
- EPS
- +103.1%
- Free cash flow
- +172.6%
Quarter to September 2026, against a year earlier
11.61
0.03
+0.26%
Follow AMRN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.54 | 1.78 | 1.40 | 1.36 | |
P/FCF ratio |
7.25 | 21.35 | 11.86 | 43.21 | |
P/Operating CF |
29.44 | 50.26 | 47.43 | 18.96 | |
P/B ratio |
0.61 | 0.75 | 0.67 | 0.63 | |
Price to Tangible BV |
0.63 | 0.77 | 0.69 | 0.65 | |
EV/Sales |
(0.19) | 0.19 | 0.06 | 0.02 | |
EV/EBITDA |
1.15 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.90) | 2.27 | 0.52 | 0.77 | |
EV/FCF |
(0.90) | 2.28 | 0.52 | 0.78 | |
Quick Ratio |
2.48 | 2.48 | 2.32 | 2.21 | |
Current Ratio |
3.50 | 3.67 | 3.48 | 3.34 | |
Net Debt/EBITDA |
188.02 | 27.68 | 28.80 | 53.83 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.27 | 0.29 | 0.33 | 0.32 | |
Operating CF/Net income |
37.64 | (0.86) | (0.61) | (12.48) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.63% | 11.31% | 10.34% | 10.91% | |
Selling, General and Administrative Expense of Revenue |
36.25% | 52.56% | 46.78% | 40.76% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
3.48% | 4.98% | 5.16% | 3.28% | |
Graham Net Nets |
1.56 | 1.27 | 1.42 | 1.51 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.04%) | (8.15%) | (11.15%) | (13.39%) | |
Free Cash Flow Yield |
13.80% | 4.68% | 8.43% | 2.31% | |
Revenue per Share |
1.89 | 2.03 | 2.15 | 2.37 | |
Operating CF per Share |
0.44 | 0.32 | 0.30 | 0.74 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.44 | 0.32 | 0.30 | 0.74 | |
Cash per Share |
15.49 | 15.12 | 14.70 | 14.59 | |
Shareholders Equity per Share |
21.28 | 21.31 | 21.45 | 22.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.28 | 21.31 | 21.45 | 22.13 | |
Free Cash Flow |
9.22 | 6.60 | 6.39 | 15.28 | |
Working Capital |
437.74 | 438.56 | 446.37 | 455.42 | |
Net Current Asset Value |
423.21 | 422.01 | 429.67 | 438.39 | |
EV/EBIT |
1.05 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
119.44 | 106.02 | 107.39 | 124.56 | |
Average Payables |
38.57 | 31.75 | 46.91 | 42.86 | |
Average Inventory |
171.78 | 167.66 | 171.54 | 180.98 | |
Average Assets |
646.95 | 647.24 | 650.72 | 678.06 | |
Average Common Equity |
451.65 | 454.27 | 461.55 | 472.73 |
Columns are period end dates · fundamentals updated 2 Nov 2026